Table 1.
Characteristics of trials meeting inclusion criteria, stratified by era (pre- vs post-Darby publication).
| All Trials | 2013 or Earlier | 2014 or Later | |
|---|---|---|---|
| N (%) | N (%) | N (%) | |
| Total | 256 (100) | 104 (41) | 152 (59) |
| Cancer Type | |||
| Esophagus | 81 (32) | 26 (25) | 55 (36) |
| Lung | 80 (31) | 30 (29) | 50 (33) |
| Breast | 72 (28) | 35 (34) | 37 (24) |
| Other | 23 (9) | 13 (13) | 10 (7) |
| Trial Phase | |||
| II | 122 (48) | 54 (52) | 68 (45) |
| III | 134 (52) | 50 (48) | 84 (55) |
| Primary Endpoint | |||
| Cancer Control | 199 (78) | 78 (75) | 121 (80) |
| Patient Reported Toxicity | 7 (3) | 3 (3) | 4 (3) |
| Physician Reported Toxicity | 41 (16) | 19 (18) | 22 (14) |
| Other | 8 (3) | 4 (4) | 5 (3) |
| Cardiotoxicity Endpoint | |||
| Primary | 5 (2) | 1 (1) | 4 (3) |
| Secondary | 8 (3) | 3 (3) | 5 (3) |
| None | 243 (95) | 100 (96) | 143 (94) |
| Concurrent Systemic Therapy | |||
| Yes | 152 (59) | 53 (51) | 99 (65) |
| No | 104 (41) | 51 (49) | 53 (35) |
| Planned Enrollment | |||
| 100-499 | 202 (79) | 81 (78) | 121 (80) |
| 500-999 | 35 (14) | 13 (13) | 22 (14) |
| >1000 | 18 (7) | 9 (9) | 9 (6) |
| SBRT a Included | |||
| Yes | 9 (4) | 2 (2) | 7 (5) |
| No | 247 (96) | 102 (98) | 145 (95) |
| Proton Therapy Included | |||
| Yes | 10 (4) | 7 (7) | 3 (2) |
| No | 246 (96) | 97 (93) | 149 (98) |
a
Stereotactic body radiation therapy.